Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 Biomarker disease BEFREE Diffuse gliomas can be separated in astrocytoma and oligodendroglioma based on IDH1/2, ATRX, and TP53 mutational status. 31714292 2020
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 Biomarker disease BEFREE Patient KK was a 68-yr-old female who was found to have a large, left-sided insular mass that was shown to be an oligodendroglioma WHO grade II, positive for codeletion 1p/19q and IDH1 mutant on biopsy. 31058967 2020
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant. 30710203 2019
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma. 31371189 2019
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE The reported two cases were initially diagnosed as oligodendroglioma with 1p/19q-codeletion and mutation of <i>isocitrate dehydrogenase 1 (IDH1)</i>-R132H. 31508376 2019
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE The DSC-MRI procedure may provide insight into the IDH1/2 mutation and ATRX expression status and MGMT methylation profile of diffuse glioma; however, taking integrated oligodendroglioma into account limits the diagnostic performance of rCBV in non-invasively predicting the molecular subtype. 29468261 2019
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE Secondly, when analyzed in molecular subgroups, we were similarly unable to detect a significant PFS or OS benefit in IDH MT/codel subgroup (N = 269; HR 1.47; 95% CI 0.92-2.34; P = 0.11 and HR 1.54; 95% CI 0.78-3.05; P = 0.21, respectively), oligodendroglioma with IDH MT/codel subgroup (N = 233; HR 1.33; 95% CI 0.79-2.21; P = 0.28 and HR 1.16; 95% CI 0.53-2.54; P = 0.70, respectively) or other relevant subgroups. 30206763 2018
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 Biomarker disease BEFREE In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second. 29077933 2018
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE Furthermore, identification of a common IDH1 mutation in enchondroma and oligodendroglioma-matched pair specimens supports the hypothesis that IDH1/2 mosaicism initiates tumorigenesis. 29224049 2018
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE Trisomy of chromosome 7 in IDH mutated astrocytoma and PTEN mutations in IDH mutated oligodendroglioma are potential markers of poor prognosis, but require confirmation in larger series. 29663171 2018
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE 36 (57%) had oligodendroglioma and 27 astrocytoma.IDH-1 mutation was present in 53 (84%). 30292978 2018
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE Distinct spectral profiles were observed for lesions with IDH-mutated genotypes, between astrocytoma and oligodendroglioma histologies, as well as for tumors that had undergone MP. 28327577 2017
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 Biomarker disease BEFREE In the 2016 WHO classification, the diagnosis of oligodendroglioma has been restricted to IDH mutated, 1p19q codeleted tumors (IDHmut-codel). 29186201 2017
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE Triple-positive (IDH1 and TERT mutation with 1p19q codeletion) glioma tended to be oligodendroglioma present with much better clinical outcome compared to TERT mutation only group who is glioblastoma inclined (median overall survival 39 months VS 18 months). 28915860 2017
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE Three GBM-O samples had IDH1 (p.R132H) mutations; two of these also demonstrated 1p/19q co-deletion and had a proneural transcriptional profile, a molecular signature characteristic of oligodendroglioma. 26757882 2016
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE One hundred twenty-six tumors could be classified: 20 as type II (IDH mutation [mut], "astrocytoma"), 49 as type I (1p/19q codeletion, "oligodendroglioma"), 55 as type III (7+/10q- or TERTmut and 1p/19q intact, "glioblastoma"), and 2 as childhood glioblastoma (H3F3Amut), leaving 7 unclassified (total 91% classified). 26354927 2016
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE ATRX retention in IDH1/2 mutant tumors was strongly associated with LOH 1p/19q and oligodendroglioma histology (p < 0.0001). 27311324 2016
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE Our data reveal that the methylation profiles in 23 of the 25 GC tumors corresponded to either IDH mutant astrocytoma (n = 6), IDH mutant and 1p/19q codeleted oligodendroglioma (n = 5), or IDH wild-type glioblastoma including various molecular subgroups, i.e., H3F3A-G34 mutant (n = 1), receptor tyrosine kinase 1 (RTK1, n = 4), receptor tyrosine kinase 2 (classic) (RTK2, n = 2) or mesenchymal (n = 5) glioblastoma groups. 26493382 2016
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE We analyzed markers, including IDH mutation(IDHmut), 1p19q codeletion(1p19qcodel), ATRX expression loss(ATRX loss) and p53 overexpression, and outcomes in 159 patients with WHO grade II oligodendroglioma, oligoastrocytoma, and astrocytoma (2003-2012). 26210286 2015
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE A better prognosis was significantly associated with combined IDH1 mutation and MGMT methylation status (both positive vs both negative, HR 0.079 [95% CI 0.008-0.579], p=0.012), as well as histology (OG vs DA and OA, HR 0.158 [95% CI 0.022-0.674], p=0.011) and tumor size (<6 cm vs ≥6 cm, HR 0.120 [95% CI 0.017-0.595], p=0.008). 26276726 2015
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 Biomarker disease BEFREE In addition, the aberration profiles of IDH1 and BRAF suggest that the oligodendroglioma arose independent of cerebellar pilocytic astrocytoma. 23082883 2013
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111). 23934175 2013
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE The oligodendroglioma model presented here is a valuable model for further functional elucidation of the effects of IDH1 mutations on tumor metabolism and may aid in the rational development of novel therapeutic strategies for the large subgroup of gliomas carrying IDH1 mutations. 24252742 2013
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE The mutation analysis performed on the latter case with DNA separately sampled from the oligodendroglioma- like area and the astrocytoma-like area detected IDH1 G395A in both areas. 22385787 2012
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma
0.400 GeneticVariation disease BEFREE Both 1p19q codeletion and IDH-1 mutation predict outcome of patients with both oligodendroglioma and AO. 22396073 2012